Katarina Moretto

Katarina Moretto

Auto-generated profile, based on publicly available information

Katarina Moretto

Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
NPNestor Prieto-Dominguez
Nestor Prieto-Dominguez
PGParan Goel
Paran Goel
OOOluwagbemiga A. Ojo
Oluwagbemiga A. Ojo
KMKatarina Moretto
Katarina Moretto
AHAlisha Holtzhausen
Alisha Holtzhausen
EUEric Ubil
Eric Ubil
Traditional anticancer therapies induce tumor cell death and subsequent release of damage-associated molecular patterns (DAMPs) that activate the innate inflammatory response. Paradoxically, after treatment, macrophages often adopt a pro–wound healing, rather than proinflammatory, phenotype and contribute to cancer progression. We found that in areas proximal to DAMP release, tumor cells upregulate the expression of Pros1. Tumor-secreted Pros1 binds to the macrophage Mer receptor, consequently limiting responsiveness to DAMPs by preventing Toll-like receptor signal transduction. Pharmacological inhibition of PTP1b signaling downstream of Mer rescued the proinflammatory response, even in the presence of Pros1. Combining protein tyrosine phosphatase (PTP) inhibition with traditional therapeutics, such as chemo- or radiotherapy, rescued the innate immune response to DAMPs, increased immune infiltration, and resulted in a 40% to 90% reduction in tumor growth in multiple treatment-refractory preclinical models. Our findings suggest using PTP1b inhibitors may be a tumor agnostic means of improving the efficacy of some of the most widely used anticancer therapeutic agents.

2 May 2025
Verified
Other
Open access
NPNestor Prieto-Dominguez
Nestor Prieto-Dominguez
PGParan Goel
Paran Goel
OOOluwagbemiga A. Ojo
Oluwagbemiga A. Ojo
KMKatarina Moretto
Katarina Moretto
AHAlisha Holtzhausen
Alisha Holtzhausen
EUEric Ubil
Eric Ubil
Supplemental Figure 22. Tumor cell secretions do not suppress MyD88 levels of naïve macrophages.

2 May 2025
Verified
Other
Open access
NPNestor Prieto-Dominguez
Nestor Prieto-Dominguez
PGParan Goel
Paran Goel
OOOluwagbemiga A. Ojo
Oluwagbemiga A. Ojo
KMKatarina Moretto
Katarina Moretto
AHAlisha Holtzhausen
Alisha Holtzhausen
EUEric Ubil
Eric Ubil
Supplemental Figure 9. Flow cytometry gating strategy to identify live CD45+ immune cells.

2 May 2025
Verified
Other
Open access
PDF file
NPNestor Prieto-Dominguez
Nestor Prieto-Dominguez
PGParan Goel
Paran Goel
OOOluwagbemiga A. Ojo
Oluwagbemiga A. Ojo
KMKatarina Moretto
Katarina Moretto
AHAlisha Holtzhausen
Alisha Holtzhausen
EUEric Ubil
Eric Ubil
Supplemental Figure 11. Clustering and characterization of intra-tumoral macrophages identifies M1 and M0/M2 subsets.

2 May 2025
Verified
Other
Open access
PDF file
NPNestor Prieto-Dominguez
Nestor Prieto-Dominguez
PGParan Goel
Paran Goel
OOOluwagbemiga A. Ojo
Oluwagbemiga A. Ojo
KMKatarina Moretto
Katarina Moretto
AHAlisha Holtzhausen
Alisha Holtzhausen
EUEric Ubil
Eric Ubil
Supplemental Figure 12. Macrophage pathway analysis identifies upregulated signaling networks for each cluster

2 May 2025
Verified
Other
Open access
PDF file
NPNestor Prieto-Dominguez
Nestor Prieto-Dominguez
PGParan Goel
Paran Goel
OOOluwagbemiga A. Ojo
Oluwagbemiga A. Ojo
KMKatarina Moretto
Katarina Moretto
AHAlisha Holtzhausen
Alisha Holtzhausen
EUEric Ubil
Eric Ubil
Supplemental Figure 16. Neutrophil clusters and associated gene expression identify both pro- and anti-tumor subsets though there is a general expansion after combination therapy.